1. 1. This chapter shall not create a private cause of action against a manufacturer of an investigational drug, biological product, or device, or an individualized investigational treatment, against an eligible facility, or against any other person or entity involved in the care of an eligible patient using the investigational drug, biological product, or device, or the individualized investigational treatment for any harm done to the eligible patient resulting from the investigational drug, biological product, or device, or the individualized investigational treatment, if the manufacturer, eligible facility, or other person or entity is complying in good faith with the terms of this chapter and has exercised reasonable care.
2. 2. This chapter shall not affect any mandatory health care coverage for participation in clinical trials under Title XIII, subtitle 1.

Section amended

2017 Acts, ch 130, §8; 2025 Acts, ch 80, §7